Overview
Location
United States, Massachusetts, Cambridge
Employees
11-50
Total raised
$15M
Founded date
2013
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 28, 2017 | Charting the growth in the reproductive health genetic testing market | But now there has been progress in different methods of reproductive genetic testing. For instance, a recent explosion of the utilization of additional non-invasive prenatal testing (NIPT), and the continuous expansion of upstream preconcep... |
| Nov 16, 2015 | Boy’s mystery illness puts team of global scientists on the case | Pulse of Longwood takes you inside one of the nation’s largest hubs of hospitals and biomedical research. Five-year-old LamLam Guo has spent most of his life in hospitals. Since he was a baby, he has suffered from weak muscles and has had t... |
| Feb 18, 2015 | The Precision Medicine Initiative: A child-centered perspective | By Patrice Milos A child is sick, showing symptoms her parents cannot identify. Something is seriously wrong, but what? The family turns to Boston Children’s Hospital for answers. Yet, even with today’s medical advances, a precise diagnosis... |
| Jan 28, 2015 | Claritas Genomics Secures $15M in Series B Funding | Claritas Genomics, a Cambridge, MA-based clinical genetic diagnostic testing company, secured $15m in Series B funding. The round was led by WuXi NextCODE Genomics with participation from existing investors Boston Children’s Hospital, Cerne... |
| Jan 9, 2015 | 15 health care predictions for 2015 | By Vector Staff 2014 continued to see massive evolution in health care – from digital health innovations to the maturation of technologies in genomics, genome editing and regenerative medicine to the configuration of the health care system ... |
| Sep 15, 2014 | A 28-gene test for kidney disease | Understanding the genetic causes of nephrotic syndrome could lead to better drug treatments that reduce the need for dialysis or a kidney transplant. (Image: Wikimedia Commons) By Nancy Fliesler Nephrotic syndrome is one of the worst diseas... |
| May 14, 2014 | Direct-to-consumer genetic testing: a case of potential harm | By Nancy Fliesler Last November, the U.S. Food and Drug Administration issued a “cease and desist” order to 23andMe, a major purveyor of direct-to-consumer (DTC) genetic testing. In its letter to the company—issued after three prior warning... |
| Oct 7, 2013 | We have a $1,000 genome. Now what? | By Tom Ulrich The Human Genome Project’s push to completely sequence the human genome ran a tab of roughly $2.7 billion and required the efforts of 20 research centers around the world using rooms full of equipment. But that was using techn... |
| Charting the growth in the reproductive health genetic testing market | The reproductive genetic testing market is poised for substantial investment and growth as demand continues, reimbursement improves, and the technology expands to additional, novel applications. The market has historically been dominated by... |